LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Closed

Sector Healthcare

1,130.9 -1.48

Buy Sell

Overview

Share price change

24h

Current

Min

1129.97

Max

1135.51

Key metrics
By Trading Economics
Income	710M 1.4B
Sales	400M 3.6B
P/E Sector Avg	31.03 103.001
EPS	11.56
Profit margin	40.346
Employees	13,450
EBITDA	933M 1.8B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+4.43 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	130B
Previous open	1132.38
Previous close	1130.9

News Sentiment

By Acuity

13%

87%

82 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 1199.12 Support & Resistance

Regeneron Pharmaceuticals Inc Chart

Related News

8 Jul 2024, 12:00 UTC

Earnings

Regeneron Expects Earnings Hit After $24 Million R&D Charge

2 May 2024, 11:02 UTC

Earnings

Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales

2 Feb 2024, 11:59 UTC

Earnings

Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products

1 Aug 2024, 11:50 UTC

Earnings

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 Aug 2024, 10:37 UTC

Earnings

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 Aug 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q EPS $12.41 >REGN

1 Aug 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q Net $1.43B >REGN

1 Aug 2024, 10:30 UTC

Earnings

Regeneron Pharma 2Q Rev $3.55B >REGN

20 Jun 2024, 20:16 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 Jun 2024, 18:09 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 Jun 2024, 11:00 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

2 May 2024, 10:32 UTC

Earnings

Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN

2 May 2024, 10:32 UTC

Earnings

Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 May 2024, 10:31 UTC

Earnings

Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN

2 May 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q Rev $3.15B >REGN

2 May 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q Adj EPS $9.55 >REGN

2 May 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q EPS $6.27 >REGN

2 May 2024, 10:30 UTC

Earnings

Regeneron Pharma 1Q Net $722M >REGN

11 Apr 2024, 13:47 UTC

Hot Stocks

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

5 Feb 2024, 12:00 UTC

Top News

What a $200 Billion Blockbuster Drug Reveals About Big Pharma's Playbook -- Heard on the Street -- WSJ

2 Feb 2024, 17:05 UTC

Earnings

Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com

2 Feb 2024, 14:13 UTC

Earnings

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High -- IBD

2 Feb 2024, 11:36 UTC

Earnings

Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN

2 Feb 2024, 11:36 UTC

Earnings

Regeneron Pharma Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 Feb 2024, 11:36 UTC

Earnings

Regeneron Pharma Sees 2024 Adjusted R&D Spending $4.3B-$4.5B >REGN

2 Feb 2024, 11:31 UTC

Earnings

Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31% to $3.22B >REGN

2 Feb 2024, 11:31 UTC

Earnings

Regeneron Pharma 4Q U.S. Eylea HD, Eylea Sales $1.46B >REGN

2 Feb 2024, 11:30 UTC

Earnings

Regeneron Pharma 4Q EPS $10.19 >REGN

2 Feb 2024, 11:30 UTC

Earnings

Regeneron Pharma 4Q Rev $3.43B >REGN

2 Feb 2024, 09:37 UTC

Earnings

These Stocks Are Moving the Most Today: Meta, Amazon, Apple, Intel, Deckers, Skechers, Clorox, and More -- Barrons.com

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

4.43% upside

12 Months Forecast

Average 1,181.61 USD 4.43%

High 1,292 USD

Low 870 USD

Based on 19 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Regeneron Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 1199.12Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

82 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.